Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection / L. Montefusco, M. Ben Nasr, F. D'Addio, C. Loretelli, A. Rossi, I. Pastore, G. Daniele, A. Abdelsalam, A. Maestroni, M. Dell'Acqua, E. Ippolito, E. Assi, V. Usuelli, A.J. Seelam, R.M. Fiorina, E. Chebat, P. Morpurgo, M.E. Lunati, A.M. Bolla, G. Finzi, R. Abdi, J.V. Bonventre, S. Rusconi, A. Riva, D. Corradi, P. Santus, M. Nebuloni, F. Folli, G.V. Zuccotti, M. Galli, P. Fiorina. - In: NATURE METABOLISM. - ISSN 2522-5812. - 3:6(2021), pp. 774-785. [10.1038/s42255-021-00407-6]
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
L. MontefuscoPrimo
;M. Ben NasrSecondo
;F. D'Addio;C. Loretelli;A. Rossi;I. Pastore;A. Abdelsalam;A. Maestroni;M. Dell'Acqua;E. Ippolito;E. Assi;V. Usuelli;A.J. Seelam;P. Morpurgo;M.E. Lunati;S. Rusconi;A. Riva;P. Santus;M. Nebuloni;F. Folli;G.V. Zuccotti;M. GalliPenultimo
;P. Fiorina
Ultimo
2021
Abstract
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.File | Dimensione | Formato | |
---|---|---|---|
s42255-021-00407-6-3.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.1 MB
Formato
Adobe PDF
|
2.1 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.